SCHEMBL4585137

SCHEMBL4585137

ClCc1ccc(Br)cc1OC1CCCCC1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPY1R P25929 1/20 0.49
NPY2R P49146 1/20 0.49
KMT2A Q03164 3/20 0.40
CSNK2A1 P68400 2/20 0.40
MEN1 O00255 2/20 0.40
SLC6A4 P31645 3/20 0.38
HTR6 P50406 2/20 0.38
MAPT P10636 1/20 0.37
LMNA P02545 2/20 0.36
NPC1 O15118 1/20 0.36
HPGD P15428 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
KDM4E B2RXH2 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
PDE4A P27815 2/20 0.36
PDE4B Q07343 2/20 0.36
PDE4C Q08493 2/20 0.36
PDE4D Q08499 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4585924 0.84 NPY1R (0.49) NPY1RNPY2RKMT2ACSNK2A1MEN1
SCHEMBL4585621 0.81 NPY1R (0.46) NPY1RNPY2RKMT2ACSNK2A1MEN1
SCHEMBL4584526 0.80 THRA (0.53) NPY1RNPY2RKMT2AMEN1LMNA
SCHEMBL16695309 0.79 CSNK2A1 (0.46) NPY1RNPY2RKMT2ACSNK2A1SLC6A4
SCHEMBL27792295 0.78 NPY1R (0.48) NPY1RNPY2RKMT2ACSNK2A1MEN1
SCHEMBL24329333 0.77 NPY1R (0.43) NPY1RNPY2RSLC6A4HTR6
SCHEMBL22816372 0.77 CSNK2A1 (0.47) NPY1RNPY2RKMT2ACSNK2A1SLC6A4
SCHEMBL29333349 0.76 NPY1R (0.43) NPY1RNPY2RSLC6A4HTR6
SCHEMBL24329571 0.76 NPY1R (0.46) NPY1RNPY2RKMT2AMEN1SLC6A4
SCHEMBL27647596 0.74 NPY1R (0.44) NPY1RNPY2RKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100582088-C Aminoalcohol derivatives ASTELLAS PHARMA INC 2010-01-20 CN disclosed
US-7417060-B2 Aminoalcohol derivatives ASTELLAS PHARMA INC. (JP) 2008-08-26 US disclosed
CN-1906154-A Aminoalcohol derivatives FUJISAWA PHARMACEUTICAL CO (JP) 2007-01-31 CN disclosed
EP-1697301-A2 AMINOALCOHOL DERIVATIVES Astellas Pharma Inc. (JP) 2006-09-06 EP disclosed
WO-2005061433-A2 AMINOALCOHOL DERIVATIVES ASTELLAS PHARMA INC. (JP) 2005-07-07 WO disclosed
US-20050137236-A1 Aminoalcohol derivatives FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050137236-A1 Aminoalcohol derivatives GPR39, PRMT9, CHRM2 NPY1R 80/4885NPY2R 96/4885KMT2A 630/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.